Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOKGet Rating) has been assigned an average rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $47.20.

Several equities research analysts recently commented on the company. Bank of America cut their price target on Stoke Therapeutics from $43.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, March 16th. Jefferies Financial Group started coverage on Stoke Therapeutics in a research report on Monday, January 31st. They issued a “buy” rating and a $50.00 price objective for the company. Zacks Investment Research lowered Stoke Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Friday, April 1st.

Hedge funds have recently modified their holdings of the stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Stoke Therapeutics during the third quarter worth $130,000. Virtus ETF Advisers LLC lifted its position in Stoke Therapeutics by 64.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,070 shares of the company’s stock valued at $218,000 after acquiring an additional 3,568 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in Stoke Therapeutics by 9.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 10,000 shares of the company’s stock valued at $222,000 after acquiring an additional 900 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Stoke Therapeutics in the fourth quarter valued at $225,000. Finally, Invesco Ltd. lifted its position in Stoke Therapeutics by 16.5% in the third quarter. Invesco Ltd. now owns 9,325 shares of the company’s stock valued at $237,000 after acquiring an additional 1,323 shares during the last quarter. Hedge funds and other institutional investors own 99.87% of the company’s stock.

STOK opened at $13.46 on Friday. The firm has a market capitalization of $526.88 million, a PE ratio of -5.78 and a beta of 0.65. Stoke Therapeutics has a twelve month low of $12.97 and a twelve month high of $41.60. The firm’s 50-day moving average price is $20.29 and its 200 day moving average price is $21.28.

Stoke Therapeutics (NASDAQ:STOKGet Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.04). Equities analysts anticipate that Stoke Therapeutics will post -1.66 EPS for the current year.

About Stoke Therapeutics (Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Featured Articles

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.